Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Nivolumab is a programmed death receptor 1 (PD-1) inhibitor. It is part of a group of drugs known as immune checkpoint blockers, which enable potent and durable T-cell responses against several tumors. We report the case of a patient with a metastatic squamous cell carcinoma, who is being treated wi...
保存先:
主要な著者: | Marcos Oro-Ayude (著者), Hae Jin Suh-Oh (著者), Victor Sacristán-Santos (著者), Patricia Vázquez-Bartolomé (著者), Ángeles Flórez (著者) |
---|---|
フォーマット: | 図書 |
出版事項: |
Karger Publishers,
2020-02-01T00:00:00Z.
|
主題: | |
オンライン・アクセス: | Connect to this object online. |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
類似資料
-
Metastatic Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patient: A Systematic Review
著者:: Megan Wackel, 等
出版事項: (2024) -
Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
著者:: Pramod Savarapu, 等
出版事項: (2021) -
Nivolumab-associated cutaneous T-cell lymphoma
著者:: Jennifer A. Marks, MD, 等
出版事項: (2021) -
Risk Factors and Prognosis for Metastatic Cutaneous Squamous Cell Carcinoma: A Cohort Study
著者:: Jaakko S. Knuutila, 等
出版事項: (2020) -
Recurrent and Metastatic Cutaneous Squamous Cell Carcinomas in a Cohort of 774 Patients in Finland
著者:: Niina Korhonen, 等
出版事項: (2020)